Drug Discovery Market Research Reports & Industry Analysis
Drug discovery is the systematic process of identifying, designing, and developing new pharmaceutical compounds or therapies to treat specific diseases or medical conditions. This is a high-cost, risky business because only a fraction of the therapeutic targets selected for study will yield products that achieve regulatory approval by the Food & Drug Administration (FDA). To help stakeholders navigate this complex market, MarketResearch.com offers a suite of comprehensive drug discovery reports on industries big and small.
Understanding the Drug Discovery Market
- Our compilation of reports features thousands of reports from leading research firms, allowing you to access highly targeted information.
- We provide a rich repository of data, including analysis of drug discovery market trends, forecasts, growth opportunities, and strategies.
- We also provide expert commentary on disruptive technologies and the use of artificial intelligence, machine learning, and blockchain in drug discovery.
Informed Insights: Your Path to Success
Whether you're an industry professional, a consultant, or an executive, our research collection provides credible data to help you make informed decisions that catalyze growth. For decades, we have served top pharmaceutical companies, investment banks, and consulting firms as a trusted research partner. Uncover new opportunities and stay ahead of the curve with MarketResearch.com's drug discovery industry reports.
Drug Discovery Industry Research & Market Reports
-
Liver Cancer Drugs
... at a CAGR of 18.4% over the analysis period 2024-2030. Targeted Drug Therapy, one of the segments analyzed in the report, is expected to record a 18.4% CAGR and reach US$5.1 Billion by the end ... Read More
-
Migraine Drugs
... CAGR of 16.0% over the analysis period 2024-2030. Acute Treatment, one of the segments analyzed in the report, is expected to record a 16.6% CAGR and reach US$7.2 Billion by the end of the analysis ... Read More
-
Pediatric Epilepsy Therapeutics
... at a CAGR of 3.3% over the analysis period 2024-2030. Third Generation, one of the segments analyzed in the report, is expected to record a 4.0% CAGR and reach US$7.0 Billion by the end of ... Read More
-
Biomarkers Market Report by Product (Consumables, Services, Software), Type (Efficacy Biomarkers, Safety Biomarkers, Validation Biomarkers), Disease (Cancer, Cardiovascular Disorders, Neurological Disorders, Immunological Disorders, Renal Disorders, and Others), Application (Diagnostics, Drug Discovery and Development, Personalized Medicine, and Others), End User (Pharmaceutical and Biotechnology Companies, Diagnostic and Research Laboratories, Hospitals and Specialty Clinics, and Others), and Region 2025-2033
... rising prevalence of chronic diseases, ongoing developments in biotechnology and genomics, the shift toward personalized medicine, continuous advancements in analytical technologies, and increasing awareness among both healthcare professionals and patients about the benefits of biomarkers ... Read More
-
Synthetic Biology
... CAGR of 27.9% over the analysis period 2024-2030. Oligonucleotides & Synthetic DNA, one of the segments analyzed in the report, is expected to record a 29.1% CAGR and reach US$39.5 Billion by the end of ... Read More
-
Acute Myeloid Leukemia (AML) Therapeutics
... Billion by 2030, growing at a CAGR of 13.3% over the analysis period 2024-2030. Cytarabine, one of the segments analyzed in the report, is expected to record a 15.3% CAGR and reach US$592.7 Million by ... Read More
-
Duchenne Muscular Dystrophy Drugs
... 2030, growing at a CAGR of 37.7% over the analysis period 2024-2030. Hospital Pharmacies, one of the segments analyzed in the report, is expected to record a 35.9% CAGR and reach US$16.5 Billion by the ... Read More
-
Pathology Instruments
... CAGR of 5.6% over the analysis period 2024-2030. Molecular Diagnostics, one of the segments analyzed in the report, is expected to record a 7.1% CAGR and reach US$1.7 Billion by the end of the analysis ... Read More
-
Small Molecule Drug Discovery
... 2030, growing at a CAGR of 8.4% over the analysis period 2024-2030. Oncology Therapeutic Area, one of the segments analyzed in the report, is expected to record a 9.8% CAGR and reach US$38.9 Billion by ... Read More
-
Amyloidosis Treatment
... CAGR of 6.8% over the analysis period 2024-2030. Chemotherapy, one of the segments analyzed in the report, is expected to record a 6.3% CAGR and reach US$3.7 Billion by the end of the analysis period. ... Read More
-
Inflammatory Bowel Disease (IBD) Therapeutics
... Billion by 2030, growing at a CAGR of 5.1% over the analysis period 2024-2030. TNF inhibitors, one of the segments analyzed in the report, is expected to record a 5.9% CAGR and reach US$14.0 Billion ... Read More
-
Drug Discovery Technologies
... at a CAGR of 8.7% over the analysis period 2024-2030. Small Molecule Drugs, one of the segments analyzed in the report, is expected to record a 8.4% CAGR and reach US$92.7 Billion by the end ... Read More
-
Lung Cancer Therapeutics
... at a CAGR of 10.8% over the analysis period 2024-2030. Non-Small-Cell Lung Cancer (NSCLC), one of the segments analyzed in the report, is expected to record a 11.9% CAGR and reach US$82.3 Billion by the ... Read More
-
Epigenetics
... 18.2% over the analysis period 2024-2030. Epigenetics Kits, one of the segments analyzed in the report, is expected to record a 19.2% CAGR and reach US$2.2 Billion by the end of the analysis period. Growth ... Read More
-
Hepatitis Therapeutics
... CAGR of 3.7% over the analysis period 2024-2030. Hepatitis C, one of the segments analyzed in the report, is expected to record a 4.0% CAGR and reach US$17.8 Billion by the end of the analysis ... Read More
-
Male Infertility
... CAGR of 5.9% over the analysis period 2024-2030. DNA Fragmentation Technique, one of the segments analyzed in the report, is expected to record a 5.6% CAGR and reach US$1.6 Billion by the end of the ... Read More
-
Myasthenia Gravis Treatment
... at a CAGR of 6.3% over the analysis period 2024-2030. Medication, one of the segments analyzed in the report, is expected to record a 5.8% CAGR and reach US$2.2 Billion by the end of the ... Read More
-
Hunter Syndrome Treatment
... at a CAGR of 5.7% over the analysis period 2024-2030. Enzyme Replacement Therapy (ERT), one of the segments analyzed in the report, is expected to record a 6.0% CAGR and reach US$1.4 Billion by the ... Read More
-
Hyaluronidase
... 8.2% over the analysis period 2024-2030. Animal-Derived, one of the segments analyzed in the report, is expected to record a 8.8% CAGR and reach US$1.4 Billion by the end of the analysis period. Growth in ... Read More
-
Metabolic Disorder Therapeutics
... at a CAGR of 6.9% over the analysis period 2024-2030. Diabetes, one of the segments analyzed in the report, is expected to record a 7.3% CAGR and reach US$91.9 Billion by the end of the ... Read More
-
Rapid Application Development
... at a CAGR of 37.6% over the analysis period 2024-2030. Tools, one of the segments analyzed in the report, is expected to record a 36.1% CAGR and reach US$465.3 Billion by the end of the ... Read More
-
Neglected Tropical Diseases Diagnosis
... 2030, growing at a CAGR of 5.6% over the analysis period 2024-2030. Conventional, one of the segments analyzed in the report, is expected to record a 4.9% CAGR and reach US$5.4 Billion by the end ... Read More
-
Desmopressin
... 5.6% over the analysis period 2024-2030. Injectable Solution, one of the segments analyzed in the report, is expected to record a 6.2% CAGR and reach US$866.1 Million by the end of the analysis period. Growth ... Read More
-
Gout Therapeutics
... CAGR of 13.4% over the analysis period 2024-2030. NSAIDs, one of the segments analyzed in the report, is expected to record a 13.2% CAGR and reach US$4.7 Billion by the end of the analysis period. ... Read More
-
1,3-Beta-Glucan Synthase Inhibitor - Pipeline Insight, 2025
... pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type. Pipeline Products covered across the following Developmental ... Read More
Research Assistance
